[Neoadyuvant endocrine therapy in breast cancer]

Area of Science:

• Oncology
• Endocrinology
• Breast Cancer Research

Context:

• Neoadjuvant chemotherapy is standard for locally advanced breast cancer, improving surgical outcomes.
• Estrogen receptor (ER)-positive tumors constitute over 80% of breast cancers, suggesting a role for endocrine therapy.
• Preoperative systemic therapy enables dynamic in vivo evaluation of prognostic and predictive factors.

Purpose:

• To review clinical evidence on neoadjuvant endocrine therapy (NET) for ER-positive breast cancer.
• To discuss the value of predictive factors in patient selection for NET.
• To explore the role of endocrine therapy as a research tool in the neoadjuvant setting.

Summary:

• Neoadjuvant endocrine therapy is feasible and safe for locally advanced breast cancer, particularly ER-positive cases.
• Emerging drugs and clinical data support the use of NET before surgery.
• NET allows in vivo assessment of tumor response and aids in identifying patients likely to benefit.

Impact:

• Enhances conservative treatment options and resectability rates for locally advanced breast cancer.
• Provides a platform for dynamic evaluation of predictive biomarkers.
• Supports personalized medicine by guiding patient selection for endocrine-based neoadjuvant strategies.